Therapeutic implications of interleukin-10 in surgical disease

Shock

Volumn 10, Issue 5, 1998, Pages 309-318

  Selzman, Craig H ^a,b   Shames, Brian D ^a   Miller, Stephanie A ^a   Pulido, Edward J ^a   Meng, Xianzhong ^a   McIntyre Jr , Robert C ^a   Harken, Alden H ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA BINDING PROTEIN; INTERLEUKIN 10; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ANIMAL; CARDIOVASCULAR DISEASE; GENETIC TRANSCRIPTION; HUMAN; IMMUNOLOGY; INFLAMMATION; INJURY; METABOLISM; PANCREATITIS; PHYSIOLOGY; REVIEW; SEPSIS; TRANSPLANTATION;

ANIMALS; CARDIOVASCULAR DISEASES; CYTOKINES; DNA-BINDING PROTEINS; HUMANS; INFLAMMATION; INTERLEUKIN-10; PANCREATITIS; PROTEIN-TYROSINE KINASES; SEPSIS; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSPLANTATION; WOUNDS AND INJURIES;

EID: 0032198695     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199811000-00001     Document Type: Review

References (156)

1. Cain BC, Meldrum DR, Selzman CH, et al.: Surgical implications of vascular endothelial physiology. Surgery 122:516-526, 1997.
2. Cain BS, Meldrum DR, Harken AH, Mcintyre Jr R: The physiologic basis for anti-cytokine clinical trials in the treatment of sepsis. J Am Coll Surg 186:337-350, 1998.
3. Zeni R, Freeman B, Natanson C: Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 25:1095-1100, 1997.
4. Selzman CH, Whitehill TA, Shames BD, Pulido EJ, Cain BS, Harken AH: The biology of estrogen-mediated repair of cardiovascular injury. Ann Thorac Surg 65:868-874, 1998.
5. Fiorentino DF, Bond MW, Mosmann TR: Two types of mouse T helper cell IV: TH2 clones secrete a factor that inhibits cytokine production by TH1 clones. J Exp Med 170:2081-2095, 1989.
6. Mosmann TR, Coffman RL: TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 7:145-173, 1989.
7. Vieira P, de Waal Malefyt R, Dang R, et al.: Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: Homology to Epstein-Barr virus open reading frame BCRF1. Proc Natl Acad Sci USA 88:1172-1991.
8. Hsu DH, de Waal Malfeyt R, Fiorentino DF, et al.: Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 250:830-832, 1990.
9. Moore KW, Vielna P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR: Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF1. Science 248:1230-1234, 1990.
10. + T cells. J Immunol 146:1341-1347, 1991.
11. de Waal Malefyt R, Haanen J, Speits H, et al.: Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of moncytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174:915-924, 1991.
12. Sheng WS, Hu S, Kravitz FH, Peterson PK, Chao CC: Tumor necorsis factor alpha upregulates human microglial production of interleukin-10 in vitro. Clin Diagn Lab Immunol 2:604-608, 1995.
13. + T cell clones and peripheral blood T cells. J Immunol 149:2378-2384, 1992.
14. O'Garra AG, Stapleton G, Dhar V, et al.: Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int Immunol 2:821-826, 1990.
15. Enk AH, Katz SI: Identification and induction of keratinocyte-derived IL-10. J Immunol 149:92-95, 1992.
16. Reglier H, Arce-Vicioso M, Fay M, Gougerot-Pociadalo MA, Chollet-Martin S: Lack of IL-10 and IL-13 production by human polymorphonuclear neutrophils. Cytokine 10:192-198, 1998.
17. Fuchs AC, Granowitz EV, Shapiro L, et al.: Clinical, hematologic, and immunologic effects of interleukin-10 in humans. J Clin Immunol 16: 291-303, 1996.
18. de Waal Malefyt R, Abrams RJ, Bennett B, Figdor CG, DeVries JE: Interleukin10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209-1220, 1991.
19. van der Poll T, Jansen J, Levi M, ten Cate H, ten Cate JH, van Deventer SJH: Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med 180:1985-1988, 1994.
20. Wanidworanun C, Strober W: Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol 151:6853-6861, 1993.
21. Cohen SB, Parry SL, Feldmann M, Foxwell B: Autocrine and paracrine regulation of human T cell IL-10 production. J Immunol 158:5596-5602, 1997.
22. Kambayashi T, Jacob CO, Strassmann G: IL-4 and IL-13 modulate IL-10 release in endotoxin-stimulated murine peritoneal mononuclear phagocytes. Cell Immunol 171:153-158, 1996.
23. van Furth AM, Verhard-Seijmonsbergen EM, van Furth R, Langermans JA: Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-alpha, IL-1 beta, and IL-10 by human leukocytes. Immunology 91:193-196, 1997.
24. Platzer C, Meisel C, Vogt K, Platzer M, Volk HD: Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int Immunol 7:517-523, 1995.
25. Mori N, Prager D: Activation of the interleukin-10 gene in the human T lymphoma line HuT 78: Identification and characterization of NF-kappa B binding sites in the regulatory region of the interleukin-10 gene. Eur J Haematol 59:162-170, 1997.
26. Chomarat P, Rissoan MC, Banchereau J, Miossec P: Interferon γ inhibits interleukin-10 production by monocytes. J Exp Med 177:523-527, 1993.
27. Li C, Goodrich JM, Yang X: Interferon-gamma (IGN-gamma) regulates production of IL-10 and IL-12 in human herpesvirus-6 (HHV-6)-infected monocyte/macrophage lineage. Clin Exp Immunol 109:421-425, 1997.
28. Donnelly RP, Freeman SL, Hayes MP: Inhibition of IL-10 expression by IFN-γ up-regulates transcription of TNF-α in human monocytes. J Immunol 155:1420-1427, 1995.
29. Liu T, Wei SHY, Ho ASY, de Wall Malefyt R, Moore KW: Expression cloning and characterization of a human IL-10 receptor. J Immunol 152:1821-1829, 1994.
30. Taniguchi T: Cytokine signaling through nonreceptor tyrosine kinases. Science 268:251-255, 1995.
31. Bach EA, M Aguet, RD Schreiber: The IFN-γ receptor: A paradigm for cytokine receptor signaling. Annu Rev Immunol 15:563-591, 1997.
32. Darnell JE: STATs and gene regulation. Science 277:1630-1635, 1997.
33. Te Velde AA, Lalefijt RDW, Huijbens RJF, de Vries JE, Figdor CG: IL-10 stimulates monocyte FcγR surface expression and cytotoxic activity: Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-gamma, IL-4, and IL-10. J Immunol 149:4048-4052, 1992.
34. Selzman CH, Shames BD, Whitehill TA, Harken AH, Mcintyre Jr RC: Class II cytokine receptor ligands inhibit human vascular smooth muscle proliferation. Surgery 124:318-327, 1998.
35. Finbloom DS, Winestock KD: IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1α and STAT3 complexes in human T cells and monocytes. J Immunol 155: 1079-1090, 1995.
36. O'Farrell AM, Liu Y, Moore KW, Mui AL: IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: Evidence for Stat3-dependent and -independent pathways. EMBO J 17:1006-1018, 1998.
37. Seger R, Krebs EG: The MAPK signalling cascade. FASEB J 9:726-735, 1995.
38. Geng Y, Gulbins E, Altman A, Lotz M: Monocyte deactivation by interleukin 10 via inhibition of tyrosine kinase activity and the Ras signaling pathway. Proc Natl Acad Sci USA 91:8602-8606, 1994.
39. Meldrum DR: Tumor necrosis factor in the heart. Am J Physiol 274: R577-R595, 1998.
40. Foey AD, Parry SL, Williams LM, Feldmann M, Foxwell BMJ, Brennan FM: Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNFα: Role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol 160:920-928, 1998.
41. Siebenlist U, Franzoso G, Brown K: Structure, regulation, and function of NF-κB. Ann Rev Cell Biol 10:405-455, 1994.
42. Shames BD, Selzman CH, Meng X, Meldrum DR, Cain BC, Harken AH: Genes Don't Count. Arch Surg 133:667-669, 1998.
43. Baldwin AS: The NF-κB and IκB proteins: New discoveries and insights. Annu Rev Immunol 14:649-681, 1996.
44. Romano MF, Lamberti A, Petrella A, et al.: IL-10 inhibits nuclear factor-kappa-B/Rel nuclear activity in CD3-stimulated human peripheral T lymphocytes. J Immunol 156:2119-2123, 1996.
45. Wang P, Wu P, Siegel MI, Egan RW, Billah MM: Interleukin (IL)-10 inhibits nuclear factor κB (NFκB) activation in human monocytes. J Biol Chem 270:9558-9563, 1995.
46. Lentsch AB, Shanley TP, Sarma V, Ward PA: In Vivo suppression of NF-κB and preservation of IκBα by interleukin-10 and interleukin-13. J Clin Invest 100:2443-2448, 1997.
47. Takeshita S, Gage JR, Kishimoto T, Vredevoe DL, Martinez-Maza O: Differential regulation of IL-6 gene transcription and expression by IL-4 and IL-10 in human monocytic cell lines. J Immunol 156:2591-2598, 1996.
48. Dokter WHA, Koopmans SB, Vellenga E: Effects of IL-10 and IL-4 on LPS-induced transcription factors (AP-1, NF-IL6, and NF-κB) which are involved in IL-6 regulation. Leukemia 10:1308-1316, 1996.
49. Bogdan C, Paik J, Vodovotz V, Nathan C: Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10. J Biol Chem 267:23301-23308, 1992.
50. Wang P, Wu P, Siegel MI, Egan RW, Billah MM: IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J Immunol 153:811-816, 1994.
51. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A: IL-10 inhibits cytokine production by activated macrophages. J Immunol 147: 3815-3822, 1991.
52. Barsig J, Kusters S, Vogt K, Volk HD, Tiegs G, Wendel A: Lipopolysaccharide-induced interleukin-10 in mice: Role of endogenous tumor necrosis factor-alpha. Eur J Immunol 25:2888-2893, 1995.
53. Sagawa K, Mochizuki M, Sugita S, Nagai K, Sudo T, Itoh K: Suppression by IL-10 and IL-4 of cytokine production induced by two-way autologous mixed lymphocyte reaction. Cytokine 8:501-506, 1996.
54. Wang P, Wu P, Anthes JC, Siegel MI, Egan RW, Billah MM: Interleukin-10 inhibits interleukin-8 production in human neutrophils. Blood 83:2678-2683, 1994.
55. Bogdan C, Vodovotz T, Nathan C: Macrophage deactivation by interleukin 10. J Exp Med 174:1549-1555, 1991.
56. Cunha FQ, Moncada S, Liew FY: Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-γ in murine macrophages. Biochem Biophys Res Commun 182:1155, 1992.
57. Aderka D: The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 7:231-240, 1996.
58. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 87: 2095-2147, 1996.
59. Jenkins JK, Malyak M, Arend WP: The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. Lymphokine Cytokine Res 13:47-54, 1994.
60. Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S: Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 179:1695-1699, 1994.
61. Marie C, Pitton C, Fitting C, Cavaillon JM: IL-10 and IL-4 synergize with TNF-alpha to induce IL-1ra production by human neutrophils. Cytokine 8:147-151, 1996.
62. Joyce DA, Gibbons DP, Green P, Steer JH, Feldmann M, Brennan RM: Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p 75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol 24:2699-2705, 1994.
63. Hart PH, Hunt EK, Bonder CS, Watson CJ, Finlay-Jones JJ: Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. J Immunol 157:3672-3680, 1996.
64. Leeuwenberg JRM, Jeunhomme TMAA, Buurman WA: Slow release of soluble TNF receptors by monocytes in vitro. J Immunol 152:4036-4043, 1994.
65. Dickensheets HL, Freeman SL, Smith JM, Donnelly RP: Interleukin-10 upregulates tumor necrosis factor receptor type-II (p75) gene expression in endotoxin-stimulated human monocytes. Blood 90:4162-4171, 1997.
66. Germann T, Partenheimer A, Rude E: Requirements for the growth of lymphocyte-Th1 clones. Eur J Immunol 20:2035-2040, 1990.
67. Matsumoto H, Suzuki K, Tsuyuguchi K, et al.: Interleukin-12 gene expression in human monocyte-derived macrophages stimulated with Mycobacterium bovis BCG: Cytokine regulation and effect of NK cells. Infect Immun 65:4405-4410, 1997.
68. Marchant A, Bruyns C, Vandenabeele P, et al.: Interleukin-10 controls interferon-γ and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 24:1167-1171, 1994.
69. Taga K, Tossato G: IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 148:1143-1148, 1992.
70. MacLennan IC, Gulbranson-Judge A, Toellner KM, et al.: The changing preference of T and B cells for partners as T-dependent antibody responses develop. Immunol Rev 156:53-66, 1997.
71. Fiorentino DF, Zlotnik A, Vieira P, et al.: IL-10 acts on the antigen presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146:3444-3451, 1991.
72. Go NF, Castle BE, Barret R, et al.: Interleukin 10, a novel B cell stimulatory factor: Unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med 172:1625-1631, 1990.
73. Fluckiger AC, Garrone P, Durand I, Galizzi JP, Banchereau J: Interleukin 10 (IL-10) upregulates functional high affinity IL-2 receptors on normal and leukemic B lymphocytes. J Exp Med 178:1473-1481, 1993.
74. Levy Y, Brouet JC: Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 93:424-428, 1994.
75. Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J: Interleukin 10 and transforming growth factor β cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med 175:671-682, 1992.
76. Rousset R, Garcia E, Defrance T, et al.: Inteleukin-10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 89:1890-1893, 1992.
77. Carson WE, Lindemann MJ, Baiocchi R, et al.: The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 85:3577-3585, 1995.
78. Berman RM, Suzuki T, Tahara H, Robbins PD, Narula SK, Lotze MT: Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol 157:231-238, 1996.
79. Zheng LM, Ojcious DM, Garaud F, et al.: Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 184: 579-584, 1996.
80. Parsons PE, Moss M, Vannice JL, Moore EE, Moore FA, Repine JE: Circulating IL-1ra and IL-10 levels are increased but do not predict the development of acute respiratory distress syndrome in at-risk patients. Am J Respir Crit Care Med 155:1469-1473, 1997.
81. Lyons A, Kelly JL, Rodrick ML, Mannick JA, Lederer JA: Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection. Ann Surg 226:450-460, 1997.
82. Pezzilli R, Billi P, Miniero R, Barakat B: Serum interleukin-10 in human acute pancreatitis. Dig Dis Sci 42:1469-1472, 1997.
83. Marchant A, Deviere J, Byl B, De Groote D, Vincent JL, Goldman M: Interleukin-10 production during septicaemia. Lancet 343:707-708, 1994.
84. Neidhart R, Keel M, Steckholzer U, et al.: Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. J Trauma 42:863-870, 1997.
85. Uyemura K, Demer LL, Castle SC, et al.: Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 97:2130-2138, 1996.
86. Sablotzki A, Welters I, Lehmann N, et al.: Plasma levels of immunoinhibitory cytokines interleukin-10 and transforming growth factor-beta in patients undergoing coronary bypass grafting. Eur J Cardiothorac Surg 11:763-768, 1997.
87. Tabardel Y, Duchateau J, Schmartz D, et al.: Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. Surgery 119:76-80, 1996.
88. Wan S, LeClerc JL, Schmartz D, et al.: Hepatic release of interleukin-10 during cardiopulmonary bypass in steroid-pretreated patients. Am Heart J 133:335-339, 1997.
89. Wan S, DeSmet JM, Barvais L, Goldstein M, Vincent JL, LeClerc JL: Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 112: 806-811, 1996.
90. Marriot JB, Goldman JH, Keeling PJ, Baig MK, Dalgleish AG, McKenna WJ: Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. Heart 75:287-290, 1996.
91. Shibata M, Endo S, Inada K, et al.: Elevated plasma levels of interleukin-1 receptor antagonist and interleukin-10 in patients with acute myocardial infarction. J Interferon Cytokine Res 17:145-150, 1997.
92. Hempel L, Korholz D, Nussbaum P, Bonig H, Burdach S, Zintl F: High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation. Bone Marrow Transplant 20:365-368, 1997.
93. Azzawi M, Hasleton PS, Grant SC, Stewart JP, Hutchinson IV, The Manchester Transplant Cytokine Group: Interleukin-10 in human heart transplantation: An in situ hybridization study. J Heart Lung Transplant 14:519-528, 1995.
94. Xu GP, Sharma VK, Li B, et al.: Intragraft expression of IL-10 messenger RNA: A novel correlate of renal allograft rejection. Kid Int 48:1504-1507, 1995.
95. Toogood GJ, Rankin AM, Tam PK, Morris PJ, Dallman MJ: The immune response following small bowel transplantation. II. A very early cytokine response in the gut-associated lymphod tissue. Transplantation 63:1118-1123, 1997.
96. Bodger K, Wyatt JI, Heatley RV: Gastric mucosal secretion of interleukin-10: Relations to histopathology, Helicobacter pylori status, and tumour necrosis factor-alpha secretion. Gut 40:739-744, 1997.
97. Haeberle HA, Kubin M, Bamford KB, et al.: Differential stimulation of interleukin-12 (IL-12) and IL-10 by live and killed Helicobacter pylori in vitro and association of IL-12 production with gamma interferon-producing T cells in the human gastric mucosa. Infect Immun 65:4229-4235, 1997.
98. Kuzushita N, Hayashi N, Katayama K, et al.: High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C. Scand J Gastroenterol 32:169-174, 1997.
99. Kroning H, Tager M, Thiel U, et al.: Overproduction of IL-7, IL-10 and TGF-beta 1 in multiple myeloma. Acta Haematol 98:116-118, 1997.
100. Weckmann AL, Alcocer-Varela J: Cytokine inhibitors in autoimmune disease. Semin Arthritis Rheum 26:539-557, 1996.
101. Harley JB, Gallagher G: Lupus and interleukin-10. J Rheumatol 24: 2273-2275, 1997.
102. Biffl WL, Moore EE, Moore FA, Peterson VM: Interleukin-6 in the injured patient: Marker of injury or mediator of inflammation. Ann Surg 224:647-664, 1996.
103. Kelly JL, Lyons A, Soberg CC, Mannick JA, Lederer JA: Anti-interleukin-10 antibody restores burn-induced defects in T-cell function. Surgery 122:146-152, 1997.
104. Remick DG, Garg SJ, Newcomb DE, Wollenberg G, Huie TK, Bolgos GL: Exogenous interleukin-10 fails to decrease the mortality or morbidity of sepsis. Crit Care Med 26:895-904, 1998.
105. Tonnetti L, Spaccapelo R, Cenci E, et al.: Interleukin-4 and -10 exacerbate candidiasis in mice. Eur J Immunol 25:1559-1565, 1995.
106. Napolitano LM, Campbell C: Polymicrobial sepsis following trauma inhibits interleukin-10 secretion and lymphocyte proliferation. J Trauma 39:104-111, 1995.
107. Armstrong L, Millar AB: Relative production of tumor necrosis factor α and interleukin 10 in adult repiratory distress syndrome. Thorax 52:442-446, 1997.
108. Miller-Graziano CL, De AK, Kodys K: Altered IL-10 levels in trauma patients' macrophage and T lymphocytes. J Clin Immunol 15:93-104, 1995.
109. Howard M, Muchamuel T, Andrade S, Menon S: Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 177:1205-1208, 1993.
110. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL: Neutralization of IL-10 increases lethality in endotoxemia: Cooperative effects of macrophage inflammatory protein-2 and tumor necrois factor. J Immunol 155:2222-2229, 1995.
111. van der Poll T, Jansen PM, Montefut WJ, et al.: Effects of IL-10 on systemic inflammatory reponses during sublethal primate endotoxemia. J Immunol 158:1971-1975, 1997.
112. Rongione AJ, Kusske AM, Ashley SW, Reber HA, McFadden DW: Interleukin-10 prevents early cytokine release in severe intraabdominal infection and sepsis. J Surg Res 70:107-112, 1997.
113. Sawa T, Corry DB, Gropper MA, Ohara M, Kurahashi K, Wiener-Kronish JP: IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia. J Immunol 159:2858-2866, 1997.
114. Cox G: IL-10 enhances resolution of pulmonary inflammation in vivo by promoting apoptosis of neutrophils. Am J Physiol 271:L566-L571, 1996.
115. Brandtzaeg P, Osnes L, Ovstebo R, Joo GB, Westvik AB, Kerulf P: Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: Identification of interleukin-10 as a major functional deactivator of human monocytes. J Exp Med 184:51-60, 1996.
116. Pajkrt D, Camoglio L, Tiel-van Buul MCM, et al.: Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: Effect of timing of recombinant human IL-10 administration. J Immunol 158:3971-3977, 1997.
117. Pajkrt D, van der Poll T, Levi M, et al.: Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood 89: 2701-2705, 1997.
118. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W: Interleukin-10 deficient mice develop chronic enterocolitis. Cell 75:263-274, 1993.
119. Braunstein J, Qiao L, Autschbach F, Schurmann G, Meuer S: T cells of the human intestinal lamina propria are high producers of interleukin-10. Gut 41:215-220, 1997.
120. Fukushima K, West GA, Dobrea GM, Sasaki I, Matsuno S, Fiocchi C: Differential IL-10 production between ulcerative colitis (UC) and Crohn's disease (CD): Enhanced levels in UC are macrophage but not T cell derived. Gastroenterology 108:A820 (Abstract), 1995.
121. Schreiber S, Heinig T, Thiele HG, Raedler A: Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 108:1434-1444, 1995.
122. Madsen KL, Tavernini MM, Fedorak RN: Interleukin-10 modulates ion transport in rat small intestine. Gastroenterology 111:936-944, 1996.
123. Madsen KL, Hibbard J, Tavernini MM, Fedorak RN: Interleukin-10 prevents disruption of T84 monolayer barrier integrity and limits chloride secretion. Gastroenterology 110:A953 (Abstract), 1996.
124. van Deventer SJ, Elson CO, Fedorak RN, for the Crohn's Disease Study Group: Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's disease study group. Gastroenterology 113: 383-389, 1997.
125. Norman JG, Franz MG, Riker A, Fabri PJ, Gower WR: Rapid elevation of systemic cytokines during acute pancreatitis and their origination withing the pancreas. Surg Forum 45:148-150, 1994.
126. Grewal HP, el Din AM, Gaber L, Kotb M, Gaber O: Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNFα polyclonal antibody. Am J Surg 167:214-219, 1994.
127. Formela LJ, Wood LM, Whittakker M, Kingsnorth AN: Amelioration of experimental acute pancreatitis with a potent platelet-activating factor antagonist. Br J Surg 81:1783-1785, 1994.
128. Norman J, Franz M, Messina J, et al.: Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery 117:648-655, 1995.
129. Van Laethem J, Marchant A, Delvaux A, et al.: Interleukin 10 prevents necrosis in murine experimental pancreatitis. Gastroenterology 108: 1917-1922, 1995.
130. Rongione AJ, Kusske AM, Kwan K, Ashley SW, Reber HA, McFadden DW: Interleukin 10 reduces the severity of acute pancreatitis in rats. Gastroenterology 112:960-967, 1997.
131. Bleeker MW, Netea MG, Kullberg BJ, Van Der Ven-Jongekrijg J, Van Der Meer JW: The effects of dexamethasone and chlorpromazine on tumour necrosis factor-alpha, interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-10 in human volunteers. Immunology 91:548-552, 1997.
132. Willems F, Marchant A, Delville JP, et al.: Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 24:1007-1009, 1994.
133. Song S, Ling-Hu H, Roebuck K, Rabbi MF, Donnelly RP, Finnegan A: Interleukin-10 inhibits interferon-γ induced intracellular adhesion molecule-1 gene transcription in human monocytes. Blood 89:4461-4469, 1997.
134. Vasse M, Paysant J, Soria J, Mirshahi SS, Vannier JP, Soria C: Down-regulation of fibrinogen biosynthesis by IL-4, IL-10, and IL-13. Br J Haemotol 93:955-961, 1996.
135. Selzman CH, McIntyre Jr R, Shames BD, Whitehill TA, Banerjee A, Harken AH: Interleukin-10 inhibits human vascular smooth muscle proliferation. J Mol Cell Cardiol 30:889-896, 1998.
136. Hess PJ, Seeger JM, Huber TS, et al.: Exogenously administered interleukin-10 decreases pulmonary neutrophil infiltration in a tumor necrosis factor-dependent murine model of acute visceral ischemia. J Vasc Surg 26:113-118, 1997.
137. Lane JS, Todd KE, Lewis MPN, et al.: Interleukin-10 reduces the systemic inflammatory response in a murine model of intestinal ischemia/ reperfusion. Surgery 122:288-294, 1997.
138. Engles TE, Huber TS, Zander DS, et al.: Exogenous human recombinant interleukin-10 attenuates hindlimb ischemia-reperfusion injury. J Surg Res 69:425-428, 1997.
139. Hayward R, Nossuli TO, Scalia R, Lefer AM: Cardioprotective effect of interleukin-10 in murine myocardial ischemia-reperfusion. Eur J Pharmacol 334:157-163, 1997.
140. Medbury HJ, Hibbins M, Lehnert AM, et al.: The cytokine and histological response in islet xenograft rejection is dependent upon species combination. Transplantation 64:1307-1314, 1997.
141. Van Hoffen E, Gmelig-Meyling FH, Bosboom-Kalsbeek KC, et al.: Cytokine messenger RNA expression by donor-specific T-cell clones after allogeneic heart transplantation. J Heart Lung Transplant 16:216-221, 1997.
142. Hall DM: Cells mediating allograft rejection. Transplantation 51:1141-1151, 1991.
143. Takeuchi T, Lowry RP, Konieczny B: Heart allografts in murine systems: The differential activation of TH2-like effector cells in peripheral tolerance. Transplantation 53:1281-1294, 1992.
144. Brauner R, Wu L, Laks H, et al.: Intracoronary gene transfer of immunosuppressive cytokines to cardiac allografts: Method and efficacy of adenovirus-mediated transduction. J Thorac Cardiovasc Surg 113:1059-1066, 1997.
145. Qin L, Chavin KE, Ding Y, et al.: Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model. Transplantation 59:809-816, 1995.
146. Bach JF, Fracchia GN, Chatenoud L: Safety and efficacy of therapeutic monoclonal antibodies in clinical therapy. Immunol Today 14:421-425, 1993.
147. Lowry RP, Konieczmy B, Alexander D, et al.: Interleukin-10 eliminates anti-CD3 monoclonal antibody-induced mortality and prolongs heart allograft survival in inbred mice. Transplant Proc 27:392-394, 1995.
148. Macatonia SE, Doherty TM, Knight SC, O'Garra A: Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFN-γ production. J Immunol 150:1993.
149. Chen WF, Zlotnik A: IL-10; a novel cytotoxic T-cell differentiation factor. J Immunol 146:528-534, 1991.
150. Zheng XX, Steel AW, Nickerson PW, Steurer W, Steiger J, Strom TB: Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shcok and allogeneic islet transplantation. J Immunol 154:5590-5600, 1995.
151. Huhn RD, Radwanski E, Gallo J, et al.: Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. Clin Pharmacol Ther 62:171-180, 1997.
152. Drazan KE, Wu L, Bullington D, Shaked A: Viral IL-10 gene therapy inhibits TNF-alpha and IL-1 beta, not IL-6, in the newborn endotoxemic mouse. J Pediatr Surg 31:411-414, 1996.
153. Xing Z, Ohkawara Y, Jordana M, Graham FL, Gauldie J: Adenoviral vector-mediated interleukin-10 expression in vivo: Intramuscular gene transfer inhibits cyokine reponses in endotoxemia. Gene Ther 4:140-149, 1997.
154. Zheng XX, Steel AW, Hancock WW, et al.: A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J Immunol 158:4507-4513, 1997.
155. Chernoff AE, Granowitz EV, Shapiro L, et al.: A randomized, controlled trial of IL-10 in humans. J Immunol 154:5492-5499, 1995.
156. Klava A, Windsor AC, Farmery SM, et al.: Interleukin-10. A role in the development of postoperative immunosuppression. Arch Surg 132:425-429, 1997.